Marketing & Communications

Five things for pharma marketers to know: Tuesday, June 23

Five things for pharma marketers to know: Tuesday, June 23

By

Adults dominate the ADHD prescription category; the FDA approved The Medicine Company's anticlotting drug 10 years after issuing a CRL; a survey shows personalized content can build consumer goodwill

Amicus briefs pile up in Amarin lawsuit

The Medical Information Working Group and the Washington Legal Foundation filed briefs in support of Amarin.

Five things for pharma marketers to know: Thursday, June 11

Five things for pharma marketers to know: Thursday, June 11

By

Amgen's PCSK9 inhibitor is the second in its class to get an FDA panel endorsement; a new drug could threaten Shire's hold on a rare-disease category; a study shows pharma invests less in Hispanic audiences than in other groups

21st Century Cures bill advances to House floor

21st Century Cures bill advances to House floor

By

The legislation would allow drugmakers to share economic information with payers beyond what is included on the FDA-approved label.

WebMD profit jumps 60% in the first quarter

WebMD profit jumps 60% in the first quarter

By

The company said revenue from pharmaceutical and medical device sponsorships and advertisements rose 10.7% but the company put some initiatives on hold.

Effective communication requires rethinking the patient experience

Effective communication requires rethinking the patient experience

By

The patient journey concept needs a reboot, according to executives at the inaugural MM&M Transforming Healthcare conference.

Study shows women view health differently than industry thinks they do

Study shows women view health differently than industry thinks they do

By

A deep dive by the think tank Center for Talent Innovation indicates pharma and payers need to widen their definition of health when communicating with women.

Partners+Simons CEO takes helm at parent company Myelin Health

Partners+Simons CEO takes helm at parent company Myelin Health

By

With new leadership in place, the Myelin Health agency network is seeking to acquire other agencies.

Patients do not feel connected to pharma

Patients do not feel connected to pharma

By

Wego Health says fixing this problem requires incorporating patient perspectives before and after a product launch.

OPDP finds many flaws with Luitpold video

OPDP finds many flaws with Luitpold video

By

The list of objections by the Office of Prescription Drug Promotion, which oversees medical advertising, is a familiar one, and includes concerns such as claims that go beyond the approved indication.

Five things for pharma marketers to know: Tuesday, February 10

Five things for pharma marketers to know: Tuesday, February 10

By

FDA's latest guidance says it is ok to reduce the amount of risk information in print ads, Google amplifies the health information it will serve up with searches and HBO's John Oliver takes on pharmaceutical marketing.

MM&M's top reads of 2014

MM&M's top reads of 2014

A look at the content that grabbed most reader interest over the past year.

Five things for pharma marketers to know: Tuesday, December 23

Five things for pharma marketers to know: Tuesday, December 23

By

BMS cancer drug Opdivo becomes the second PD-1 inhibitor to secure US approval ; Omnicare hit by more kickback charges; India looks to rein in pharma marketing.

Danica Patrick paces health system marketing drive

The driver on NASCAR and other racing circuits will help challenge consumers to improve their health habits.

EHRs blur line between marketing and assistance: researchers

EHRs blur line between marketing and assistance: researchers

By

A trio of doctors make a case for putting limits on digital promotions, including those in EHRs and through social networks.

Acthar marketing drives prescriptions and anger

The decades-old drug is winning prescriptions through marketing, but has a free-pass when it comes to clinical trial data.

Rep access continues to shrink

Rep access continues to shrink

By

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Vet drugmakers get Warning Letters too

Regulatory Focus reports that the regulator has issued a Warning Letter to AB Science for marketing its canine tumor drug Kinavet for unapproved, off-label uses.

Marketing tone sinks GSK recruiter

GlaxoSmithKline dismissed a marketer over its approach to clinical trial recruiting.

Takeda walks away from Omontys

The drugmaker is pulling its US marketing application for the anemia drug.

Study: sales rep limits reduce off-label prescriptions

Study: sales rep limits reduce off-label prescriptions

By

Researchers found that limiting sales rep access and interactions reduces off-label prescriptions for the previously detailed drugs, while also upping off-label prescriptions of the drugs that had not been promoted.

OPDP takes on sales aid for alcohol drug

OPDP takes on sales aid for alcohol drug

By

The advertising watchdog gave drugmaker Alvogen 15 days to make amends.

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

By

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Court reverses Risperdal decision

The Arkansas Supreme Court's decision puts $1.2 billion back into J&J's coffers.

Agnitio launches Rainmaker marketing tool

Agnitio launches Rainmaker marketing tool

By

The company unveiled the mix-and-match marketing management tool at the Eye for Pharma conference in Barcelona.

DOJ may cost Aegerion patients

The drugmaker's annual report indicates the company is concerned that an investigation into its marketing could dissuade doctors from prescribing Juxtapid.

US Attorney scrutinizes Copaxone marketing

The US Attorney's Office for the Southern District of New York is examining how Teva has marketed MS drug Copaxone and Parkinson's medication Azilect since 2006.

E-mail increasingly read on mobile devices

Movable Ink reports that 65% of Q4 emails were opened on a tablet or smartphone.

Roche silences Herceptin comparison

A court in India ruled biosimilar drug makers will not be able to cite the drug's name, efficacy or safety profile in its marketing.

UK GPs like search engines more than pharma sites

A survey of UK-based general practitioners shows industry websites are not a go-to source for information. Reps did not fare well, either.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.